Holen Sie sich die Stockscreener-App
58.22
3.91%
-2.37
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$60.59
Offen:
$60.02
24-Stunden-Volumen:
17.86M
Relative Volume:
1.43
Marktkapitalisierung:
$118.87B
Einnahmen:
$48.48B
Nettoeinkommen (Verlust:
$7.27B
KGV:
16.33
EPS:
3.5648
Netto-Cashflow:
$12.85B
1W Leistung:
-0.83%
1M Leistung:
-5.69%
6M Leistung:
+26.37%
1J Leistung:
+17.36%
1-Tages-Spanne:
$58.03
$60.09
1-Wochen-Bereich:
$57.28
$60.78
52-Wochen-Spanne:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
58.22 | 118.87B | 48.48B | 7.27B | 12.85B | 3.5648 |
LLY
Lilly Eli Co
|
963.33 | 862.01B | 72.25B | 25.28B | 5.96B | 27.78 |
JNJ
Johnson Johnson
|
227.19 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.60 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.74 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.57 | 279.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol Myers Squibb: The CAR-T Giant The Market Is Undervaluing (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.18% on May 1: Drivers Behind the Movement - TradingKey
Bristol-Myers Loses Venue Fight to Texas in Plavix Litigation - Bloomberg Law News
Big Pharma M&A set for mega year as patent expiries drive deal urgency - Reuters
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2026 Earnings Call Transcript - Insider Monkey
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook - Yahoo Finance
Bristol-Myers Squibb Co (BMY) Q1 2026 Earnings Call Highlights: - GuruFocus
Is Bristol Myers Squibb (BMY) Still Attractively Priced After Its Strong 1 Year Share Price Gain - simplywall.st
BMS brings the buzz around late-stage readouts amid a so-so Q1 - Pharmaceutical Technology
BMO raises Bristol-Myers Squibb stock price target on Eliquis beat - Investing.com Canada
SIIT U.S. Managed Volatility Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb (NYSE:BMY) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS - MarketBeat
Is Bristol-Myers Squibb Co (BMY) Overvalued After 5.2% Rally? GF - GuruFocus
Bristol-Myers Squibb (BMY) Reports Solid Q1 2026 Results with Po - GuruFocus
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Why Bristol Myers Squibb Stock Rocked the Market Today - The Motley Fool
Why Is Bristol-Myers Squibb Stock Trading Higher On Thursday? - Benzinga
Bristol Myers (BMY) Q1 2026 Earnings Transcript - The Motley Fool
MSN Money - MSN
INTECH INVESTMENT MANAGEMENT LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales - Reuters
Bristol Myers Squibb Surpasses Profit Expectations: Eliquis and Cancer Medicines Drive Growth - Devdiscourse
PUTNAM GLOBAL HEALTH CARE FUND's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb jumps after Q1 results and reaffirmed 2026 outlook - Quiver Quantitative
Bristol Myers Q1 2026 slides: growth portfolio drives revenue beat - Investing.com
Bristol Myers Squibb Company $BMY Shares Sold by Verity Asset Management Inc. - MarketBeat
Crohn’s Disease Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd - Barchart.com
Bristol Myers (BMY) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance UK
Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales - WNWN-FM
Bristol-Myers Squibb (BMY) Reports Strong Q1 2026 Earnings, Beats Expectations - GuruFocus
BMS beats estimates and reaffirms guidance - The Pharma Letter
Bristol Myers Squibb (BMY) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance UK
Bristol Myers Squibb (NYSE:BMY) Q1 2026 Earnings Beat Driven by Growth Portfolio - ChartMill
Krazati's colorectal cancer approval in jeopardy | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Bristol Myers Squibb (BMY) Q1 2026: EPS $1.31 Beats $1.19 Est., - GuruFocus
Bristol-Myers Squibb Company Stock (US0897961004): Q1 Revenues Rise 3% to $11.5 Billion - AD HOC NEWS
BRISTOL-MYERS SQUIBB ($BMY) Releases Q1 2026 Earnings - Quiver Quantitative
EDGAR Filing Documents for 0000014272-26-000008 - SEC.gov
Bristol-Myers Squibb trumps Q1 estimates, maintains full-year outlook By Investing.com - Investing.com India
Bristol Myers: Q1 Earnings Snapshot - KTVB
Bristol Myers Squibb (NYSE: BMY) posts Q1 2026 results, reaffirms 2026 guidance - Stock Titan
Bristol Myers Squibb Reports First Quarter Financial Results for 2026 - The Joplin Globe
Bristol Tops Estimates on New Drugs Ahead of Key Trial Results - Bloomberg.com
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MSN
Bristol-Myers earnings ahead: Can new drugs offset legacy slide? By Investing.com - Investing.com Nigeria
Bristol-Myers Squibb (BMY) Set for Earnings Decline Amid Positiv - GuruFocus
Fagan Associates Inc. Trims Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Does Expanded MTAP-CDx Partnership With Foundation Medicine Change The Bull Case For Bristol-Myers Squibb (BMY)? - simplywall.st
Bristol Myers, Medtronic, Gilead: Top Dividend Healthcare Stocks in April 2026News and Statistics - IndexBox
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):